<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673504</url>
  </required_header>
  <id_info>
    <org_study_id>C-II-004 / 2007-005022-71</org_study_id>
    <nct_id>NCT00673504</nct_id>
  </id_info>
  <brief_title>First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Society for Anticancer Drug Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Society for Anticancer Drug Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: to evaluate whether the addition of sunitinib prolongates the&#xD;
      Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving&#xD;
      first-line gemcitabine chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>once all patients completed treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>once all patients completed treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>at study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>at study end</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine + Sunitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Sunitinib</intervention_name>
    <description>Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1.000 mg/m2 d1,8,15q4weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who suffer from locally advanced or metastatic pancreatic cancer&#xD;
&#xD;
          -  Patients with measurable disease (at least one uni-dimensionally measurable target&#xD;
             lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST).&#xD;
&#xD;
          -  ECOG performance status 0 to 1&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  White blood cell count (WBC) &gt;= 3x10^9/L with neutrophils &gt;= 1.5 x 10^9/L, platelet&#xD;
             count &gt;= 100x10^9/L, hemoglobin &gt;= 5.6 mmol/L (9 g/dL).&#xD;
&#xD;
          -  Total bilirubin &lt; 2 x upper limit of normal.&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 x upper limit of normal, or &lt; 5 x upper limit of normal in case of&#xD;
             liver metastases.&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x upper limit of normal&#xD;
&#xD;
          -  Normal ECG without QT prolongation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resectable pancreatic cancer&#xD;
&#xD;
          -  Previous chemotherapy (for adjuvant or metastatic disease)&#xD;
&#xD;
          -  Any investigational drug within the 30 days before inclusion.&#xD;
&#xD;
          -  Prior use of sunitinib or other multitarget tyrosine kinase inhibitor&#xD;
&#xD;
          -  Pregnancy (absence to be confirmed by beta-hCG test) or lactation period.&#xD;
&#xD;
          -  Men or women of child-bearing potential who are sexually active and unwilling to use a&#xD;
             medically acceptable method of contraception during the trial.&#xD;
&#xD;
          -  Clinically symptomatic brain or meningeal metastasis. (known or suspected)&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers or digoxin).&#xD;
&#xD;
          -  History of any of the following cardiac events within the past 6 months: myocardial&#xD;
             infarction (including severe/unstable angina; coronary/peripheral artery bypass graft;&#xD;
             symptomatic congestive heart failure (CHF) &gt; NYHA Class II; cerebrovascular accident&#xD;
             or transient ischemic attack; pulmonary embolism&#xD;
&#xD;
          -  Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90&#xD;
             mm Hg despite the use of up to 3 anti-hypertensive drugs&#xD;
&#xD;
          -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or&#xD;
             chronic diarrhea&#xD;
&#xD;
          -  Previous malignancy (other than pancreatic cancer) in the last 5 years except basal&#xD;
             cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder&#xD;
             tumor [Ta, Tis and T1].&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Patients requiring long-term cortisone therapy&#xD;
&#xD;
          -  Patients requiring oral anticoagulation treatment (such as marcoumar)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe Universität; Zentrum der Inneren Medizin</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistisches Facharztzentrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg; Medizinische Fakultät</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharztpraxis</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Luedenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <link>
    <url>http://www.cesar.or.at/main.asp?VID=1&amp;kat1=49&amp;kat2=370&amp;kat3=&amp;Text=&amp;SSSID=5</url>
    <description>German Study Description on CESAR's homepage</description>
  </link>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>November 30, 2011</last_update_submitted>
  <last_update_submitted_qc>November 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Central European Society for Anticancer Drug Research-EWIV</name_title>
    <organization>Non-Profit Otrganization Oncology</organization>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>sunitinib</keyword>
  <keyword>Phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

